Background Rapid reversal of vitamin K antagonist (VKA)-induced anticoagulation is often necessary for patients needing urgent surgical or invasive procedures. The optimum means of VKA reversal has not been established in comparative clinical trials. We compared the effi cacy and safety of four-factor prothrombin complex concentrate (4F-PCC) with that of plasma in VKA-treated patients needing urgent surgical or invasive procedures.
Introduction
Patients receiving therapy with a vitamin K antagonist (VKA) have an increased risk of bleeding during surgical and procedural interventions. 1 Therefore, guidelines recommend temporary interruption of VKA therapy 5 days before elective surgery to minimise perioperative bleeding. 1 However, when patients need an urgent procedure, VKA reversal is often performed in the acute setting. Findings from a 2012 clinical trial underlined the risks involved, showing that the frequency of periprocedural bleeding in patients receiving VKA therapy was 3·3% for elective procedures, but 21·6% for emergency procedures. 2 Although vitamin K alone can be eff ective, reversal can take several hours. 3 Therefore, emergency reversal additionally necessitates the rapid replacement of vitamin K-dependent coagulation factors (ie, factors II, VII, IX, and X). In some countries, including the USA, plasma is the most commonly used agent for rapid VKA reversal. Although plasma contains the vitamin K-dependent coagulation factors, it needs ABO typing and thawing before use, and is associated with long infusion times. [4] [5] [6] More importantly, it can be associated with severe adverse outcomes including transfusion-related acute lung injury and transfusion-associated circulatory overload. 7 Non-activated prothrombin complex concentrates contain vitamin K-dependent coagulation factors and are categorised as three-factor (3F-PCC) or four-factor (4F-PCC) prothrombin complex concentrates (depending on whether they contain clinically relevant amounts of factor VII). 8 Prothrombin complex concentrates are stored at room temperature as a lyophilised powder, do not need ABO typing, can be prepared within minutes, and can be delivered in smaller volumes with shorter infusion times than can plasma. 4 Adequately powered comparative trials investigating the optimum means of VKA reversal have not been done in patients needing urgent interventions, and the best method to promptly reverse VKAs remains unclear. The only plasma-controlled randomised clinical trial was a single-centre study of 40 patients (20 per group) undergoing semiurgent cardiac surgery, which was underpowered to detect signifi cant diff erences in haemostatic effi cacy. 9 We therefore did a randomised clinical trial to compare 4F-PCC with plasma for urgent VKA reversal in patients needing urgent surgical or invasive procedures.
Methods

Study design and participants
In a randomised, open-label, active-controlled, noninferiority, multicentre, phase 3b clinical trial, we enrolled patients in 33 hospitals (18 in the USA, two in Belarus, four in Bulgaria, two in Lebanon, one in Romania, and six in Russia).
Patients with an international normalised ratio (INR) of 2·0 or higher receiving VKA therapy and needing an urgent surgical or invasive procedure within 24 h were eligible for the study. The decision about the need for surgical treatment and rapid VKA reversal was made by the clinical care teams. Exclusion criteria included requirement for a procedure for which an accurate estimate of blood loss was not possible (eg, ruptured aneurysm or trauma) or coagulopathy that could be corrected solely through administration of vitamin K and withdrawal of VKA therapy. Full inclusion and exclusion criteria are provided in the appendix.
As part of ongoing review of the investigational new drug application, the United States Food and Drug Administration (FDA) reviewed the study protocol after the trial had been initiated. On July 20, 2011, after 157 patients had been enrolled, the FDA requested that enrolment of patients needing non-surgical invasive procedures be halted because of concern that no diff erences in haemostatic effi cacy would be detected. No interim safety or effi cacy analysis was done at this time. Sites were notifi ed via letter on July 26, 2011, to immediately cease enrolment of this population, and a fi nal protocol amendment was made on Sept 7, 2011. Patients needing urgent surgical procedures continued to be enrolled as planned.
The study was approved by the independent ethics committees and institutional review boards of the participating centres, in accordance with local legal requirements; written informed consent was obtained from all patients.
Randomisation and masking
Investigators called a 24 h randomisation centre and transmitted deidentifi ed data for the randomisation procedure. We randomly assigned patients in a 1:1 ratio using a computerised system to receive either 4F-PCC (Beriplex/Kcentra/Confi dex; CSL Behring, Marburg, Germany) or plasma. Treatment assignment was done by a centrally managed, biased-coin minimisation method, 10 which is an adaptive random isation scheme (appendix). This method also controlled for balance, both overall and within centres, between treatment groups within urgent surgical or invasive procedures with use of two levels of stratifi cation: one based on the type of procedure, and one on the vitamin K dose given.
The ; and all invasive procedures (recruitment to this category was halted after protocol amendment). The second level of strata was oral vitamin K dose less than or equal to 2 mg; oral vitamin K dose more than 2 mg; and any intravenous vitamin K dose.
Surgery type was classifi ed by the treating physician according to the fi rst level of strata. The trial was open label; clinicians, study staff , and trial participants could not be blinded to treatment allocation because of the inherent characteristics of the study agents. The safety adjudication board (described below) was masked to treatment allocation.
Procedures
On day 1, patients received an intravenous infusion of study treatment based on baseline INR (assessed ≤3 h before start of infusion) and bodyweight, as described by Sarode and colleagues. 11 Patients with baseline INR of 2 or higher but lower than 4 were given 4F-PCC at a dose of 25 IU factor IX per kg bodyweight or plasma 10 mL/kg bodyweight; those with baseline INR of 4 to 6 (inclusive) were given 4F-PCC at a dose of 35 IU factor IX per kg or plasma 12 mL/kg; and those with baseline INR higher than 6 were given 4F-PCC at a dose of 50 IU factor IX per kg or plasma 15 mL/kg. Patients weighing more than 100 kg were given doses based on a bodyweight of 100 kg.
4F-PCC was given at an infusion rate of 3 IU/kg per min or less; plasma was infused as rapidly as possible and at the discretion of the treating clinical team. Thus, the plasma infusion rate represented standard care and maximised patient safety (because of concern that some patients might not be able to tolerate rapid volume load). Additionally, vitamin K was to be given to all patients according to American College of Chest Physicians 12 guidelines (≤5 mg orally, followed by 1-2 mg orally if See Online for appendix required, in patients needing urgent surgery; 10 mg by slow intravenous infusion in patients with major bleeding) or local practice if diff erent (ie, 2-10 mg). Vitamin K administration was not standardised in the protocol because of variations in local practice and guidelines.
We recorded the total volume and total infusion time of each study product. Additional blood products and haemostatic agents given were documented from randomisation to 24 h after start of study product infusion or end of the surgery, whichever came later. Blood samples were drawn for determination of INR and levels of vitamin K-dependent coagulation factors and proteins C and S before study product infusion and at 0·5 h, 1 h, 3 h, 6 h, and 24 h after start of infusion, in addition to INR at 0·5 h after end of infusion. We assessed baseline INR 3 h or less before start of infusion.
Adverse events and serious adverse events were recorded by the investigators and assessed by an independent data and safety monitoring board, unblinded to study treatment. After study launch, the data and safety monitoring board requested that a blinded safety adjudication board be established to review possible thromboembolic serious adverse events, late bleeding events, and deaths. Serious adverse events possibly consistent with thrombotic events or late bleeds, as well as death cases, were referred to the safety adjudication board. Adjudication results were provided to the data and safety monitoring board on an ongoing basis. Adverse events were assessed up to day 10 (visit window days 7-11) and serious adverse events up to day 45 (visit window days 43-51). Fluid overload events were identifi ed according to the Medical Dictionary for Regulatory Activities version 12.0 terms: fl uid overload, pulmonary oedema, cardiac failure congestive, cardiac failure chronic, and cardiac failure.
Outcomes
The primary endpoint was haemostasis during urgent surgical or invasive procedures in the intention-to-treat effi cacy (ITT-E) population. We categorised haemostasis as a binary endpoint (eff ective or non-eff ective) and this endpoint was assessed from the start of infusion to the end of the procedure. We defi ned eff ective haemostasis as: intra operative (or intraprocedural) blood loss not exceeding predicted blood loss by 30% or 50 mL; and normal or mildly abnormal haemostasis (surgeon assessed); and no administration of non-study coagulation products. Predicted blood loss was determined by the local surgeon before the start of surgery, using all clinical information available, based on the assumption of a similar non-coagulopathic patient undergoing the same intervention. We based actual blood loss (ABL) on the anaesthesiologist's record of estimated blood loss during the procedure. If an anaesthesiologist was not present during the procedure, ABL was estimated by the surgeon or physician performing the procedure. Missing haemostatic effi cacy assessments resulted in a rating of non-eff ective haemostasis.
The coprimary endpoint was rapid INR reduction (INR ≤1·3 at 0·5 h after the end of infusion) in the ITT-E population. A missing INR value at this timepoint, or administration of additional coagulation factor-containing products (non-study plasma, whole blood, or other non-study products containing coagulation factors, excluding packed red blood cells or platelets) from the start of treatment infusion to the start of the procedure resulted in a rating of no rapid decrease in INR.
There were four prespecifi ed secondary endpoints: time to INR reduction (INR ≤1·3) from start of infusion; units of red blood cells (defi ned as packed red blood cells and whole blood) given from start of surgery to 24 h after start ITT-S=intention-to-treat safety. *Study included viral follow-up to day 90. †One death occurred after study day 45 (day 48; worsening of cardiopulmonary disease). ‡Eight deaths in total in plasma group; one plasma death occurred in a completed patient and one plasma death occurred in a patient with a protocol violation.
§Patient not able to be reached for follow-up. 
Statistical analysis
There were four analysis populations (fi gure 1). The modifi ed intention-to-treat (mITT) population comprised all randomly assigned patients who were either eligible for the study but did not receive any portion of study product, or received any portion of study product. The intention-to-treat safety (ITT-S) population comprised all eligible patients from the mITT population who had received any portion of study product. The ITT-E population comprised all patients from the ITT-S population who had an INR higher than 1·3 before study product infusion and underwent the intended procedure; both the primary and coprimary endpoints were assessed in this population. Finally, the per-protocol population comprised all ITT-E patients who did not have any major protocol deviations.
The study was designed to test the hypothesis that 4F-PCC was non-inferior to plasma with regard to the primary and coprimary endpoints. We performed non-inferiority analyses in the ITT-E population via calculations (using the Newcombe-Wilson score method) 13 of the two-sided 95% CI, equivalent to a one-sided type I error rate of 0·025, for the diff erence in the proportions of patients achieving eff ective haemostasis, and separately for rapid INR reduction. For both haemostasis and INR reduction, non-inferiority was demonstrated if the lower limit of the 95% CI for the between-group diff erence (4F-PCC minus plasma) was greater than −10%. Because there is little evidence available about the haemostatic effi cacy of plasma versus placebo in patients on VKA therapy requiring urgent interventions, 14 there was no independent way of determining a non-inferiority margin in terms of preserving some portion of the eff ect of plasma versus placebo. Therefore, the non-inferiority margin of -10% was chosen based on clinical judgment. 4F-PCC could be successfully claimed to be non-inferior to plasma if non-inferiority was shown for both the primary and coprimary endpoints. If non-inferiority was shown, 4F-PCC was also to be tested for superiority compared with plasma for each of these endpoints. Superiority for an endpoint could be declared if the lower limit of the 95% CI exceeded zero. Because testing for superiority after demonstration of non-inferiority 15 does not increase type I error, a test for superiority could be done on the nominal one-sided α-level of 0·025 after demonstration of non-inferiority.
We did sample size calculations on the haemostatic effi cacy endpoint and assumed that eff ective haemostasis would be achieved by 85% of patients in the plasma group and 90% of patients in the 4F-PCC group. Based on the Newcombe-Wilson score method for CI calculations, 13 a non-inferiority margin of −10% and a dropout rate of 10%, the power to show non-inferiority would exceed 80% for two treatment groups of 88 patients (total target sample size of 176 patients). No sample size calculation was done on the INR endpoint because of the assumption of similar values for the percentages in the two study groups.
We adjusted four p values, one from each of the four secondary analyses, using the method of Holm. 16 This adjustment controlled the overall type I error and preserved the 0·05 signifi cance level. We described time to INR correction by Kaplan-Meier estimation, and assessed signifi cance of treatment diff erences using the log-rank test. Between-group diff erences for number of units of red blood cells transfused were assessed by Wilcoxon-rank-sum test. We compared the proportions of patients receiving one or more transfusions of red blood cells using NewcombeWilson score test. Plasma levels of vitamin K-dependent coagulation factors and proteins C and S were summarised by descriptive statistics and, in post-hoc analyses, group diff erences were compared by twosided Wilcoxon test.
4F-PCC (n=87)
Plasma ( We applied an ANCOVA model with predicted blood loss as a dependent variable, treatment, sex, surgical type, and study site as factors, and preinfusion haemoglobin as a covariate to establish whether predicted blood loss diff ered by treatment, which would suggest bias in the estimation of predicted blood loss.
We compared incidences of thromboembolic events, fl uid overload events, and deaths between treatment groups using Newcombe-Wilson CIs with continuity correction; other safety outcomes were analysed descriptively. We computed p values using the χ² test for homogeneity or Fisher's exact test when any of the cell sizes were small (less than fi ve).
As a result of the protocol amendment to halt enrolment of patients undergoing non-surgical invasive procedures, we also planned to do non-inferiority and superiority analyses of the haemostatic effi cacy and rapid INR reduction endpoints with the exclusion of patients needing non-surgical invasive procedures.
We analysed data with SAS version 9.3. This trial is registered at ClinicalTrials.gov, number NCT00803101.
Role of the funding source
This research was funded by CSL Behring. A steering committee of academic medical experts and representatives of the funder oversaw the design and conduct of the study. The funder participated in the selection of the board members. The funder was responsible for data collection, management, and analysis of the data according to a predefi ned statistical by noninferiority analysis in the ITT-E population. Treatment diff erence refers to between-group diff erence of 4F-PCC minus plasma. Tinted area shows zone of noninferiority, bounded by non-inferiority margin (dotted line) set at −10%. Superiority margin was set at 0% (solid line), meaning that 4F-PCC is superior to plasma if the lower limit of the 95% CI is to the right of the solid line. 4F-PCC=four-factor prothrombin complex concentrate. INR=international normalised ratio. ITT-E=intention-to-treat effi cacy. analysis plan. Preparation and review of the Article and the decision to submit for publication was done by a publication steering committee that included academic medical experts and representatives of the funder. Medical writing assistance was paid for by the funder. JNG and RS had full access to all the data in the study and took responsibility for the integrity and accuracy of the data analysis.
Results
181 patients were enrolled in the trial between Feb 3, 2009, and Nov 28, 2012 (fi gure 1); the study completed on Feb 21, 2013. We randomly assigned 90 patients to receive 4F-PCC and 91 patients to receive plasma. The mITT population included 179 patients (89 in the 4F-PCC group and 90 in the plasma group) who were randomly assigned and were either eligible or received treatment (two patients who were randomly assigned but not eligible and not treated were excluded). The ITT-S population included 176 patients (88 in the 4F-PCC group and 88 in the plasma group); reasons for loss and exclusion are shown in fi gure 1. The ITT-E population included 168 patients (87 in the 4F-PCC group and 81 in the plasma group). 28 patients (13 receiving 4F-PCC and 15 receiving plasma) who needed non-surgical invasive procedures were enrolled in the study. Table 1 shows patients' baseline data and characteristics. A detailed list of surgeries and procedures is shown in the appendix. The timing of the study treatment and interventions is shown in fi gure 2. Delivery of plasma (mean volume 818·7 mL [SD 230·8]) was as fast as could be done by the clinical team within the confi nes of local practice (including type-specifi c matching, thawing, delivery, and infusion). 4F-PCC was reconstituted from a lyophilised powder and infused (mean volume 89·7 mL [SD 31·9]). Vitamin K was given a median of 13 min before 4F-PCC (IQR 40 min before, 26 min after), and a median of 15 min before plasma (IQR 55 min before, 55 min after; post-hoc analysis). Two patients in the 4F-PCC group and no patients in the plasma group received no vitamin K during the study. 15 patients in the 4F-PCC group and 12 in the plasma group received vitamin K by a non-intravenous route. The median time from start of infusion to start of urgent surgical procedure was longer in the plasma group (8·5 h [IQR 2·8-18·7]) than in the 4F-PCC group (3·6 h [1·9-10·8]; p=0·0098; post-hoc analysis).
The primary endpoint, eff ective haemostasis in the ITT-E population, was achieved by 78 (90%) patients in the 4F-PCC group and 61 (75%) patients in the plasma group (fi gure 3). The treatment diff erence was 14·3% (95% CI 2·8 to 25·8, p=0·0142). Because the lower limit of the confi dence interval for the treatment diff erence (2·8%) exceeded the non-inferiority margin of -10%, non-inferiority was shown for haemostatic effi cacy. Analysis of superiority (lower limit of the 95% CI >0) showed that 4F-PCC was superior to plasma for this endpoint. Furthermore, we noted superiority for haemostatic effi cacy for 4F-PCC compared with plasma when the per-protocol population was used (78 [91%] patients in the 4F-PCC group vs 58 [76%] patients in the plasma group; diff erence 14·4%, 95% CI 3·0 to 26·0, p=0·0128; appendix).
Intraoperative blood loss was used as part of the assessment of haemostatic effi cacy. To address the possibility that enrolling investigators estimated predicted blood loss diff erently depending on treatment group in this open-label study, we assessed For patients undergoing any surgical procedure (ie, excluding patients who underwent non-surgical invasive procedures), the treatment diff erence for eff ective haemostasis was 15·1% (95% CI 1·9 to 28·2, p=0·0237; 65 [88%] patients in the 4F-PCC group vs 48 [73%] patients in the plasma group), demonstrating superiority of 4F-PCC compared with plasma. Although the numbers in each group were small, limiting any conclusions, the treatment diff erence was 13·3% (95% CI −11·4 to 37·9, p=0·48; 13 [100%] patients in the 4F-PCC group vs 13 [87%] patients in the plasma group) for patients needing non-surgical invasive procedures. Table 2 shows the treatment diff erences for various prespecifi ed subgroups.
The coprimary endpoint, rapid INR reduction in the ITT-E population, was achieved by 48 (55%) patients in the 4F-PCC group compared with eight (10%) patients in the plasma group. The treatment diff erence was 45·3% (95% CI 31·9 to 56·4, p<0·0001), demonstrating both non-inferiority and superiority for rapid INR reduction. Furthermore, superiority was shown for 4F-PCC compared with plasma for the per-protocol population (diff erence 45·3%, 95% CI 31·5 to 56·5, p<0·0001; 48 [56%] patients in the 4F-PCC group vs eight [11%] patients in the plasma group; appendix).
The treatment diff erence was 48·0% (95% CI 33·9 to 59·5, p<0·0001; 40 [54%] patients in the 4F-PCC group vs four [6%] patients in the plasma group) for patients undergoing any surgical procedure, demonstrating superiority of 4F-PCC over plasma. The treatment diff erence was 34·9% (95% CI −1·4 to 60·9, p=0·12; eight [62%] patients in the 4F-PCC group vs four [27%] patients in the plasma group) for patients undergoing a non-surgical invasive pro cedure. Additionally, in prespecifi ed subgroup analyses, we also noted treatment diff erences in favour of 4F-PCC for the major orthopaedic and other surgical enrolment strata (table 2) .
Patients in the 4F-PCC group achieved INR of 1·3 or lower more rapidly than did those in the plasma group (fi gure 4). 1 h after the start of infusion, 47 patients (54%) in the 4F-PCC group had an INR of 1·3 or lower compared with no patients in the plasma group (p<0·0001).
Plasma levels of vitamin K-dependent coagulation factors and proteins C and S were signifi cantly higher in the 4F-PCC group than in the plasma group at 0·5 h, 1 h, 3 h, and 6 h after start of infusion (all p values <0·05; fi gure 4).
Few patients in either group received red blood cells (14 [16%] in the 4F-PCC group and 12 [15%] in the plasma group); we noted no signifi cant diff erence between groups (p=0·83). Additionally, the mean number of red blood cell units transfused per patient was similar between groups (0·3 units [SD 0·9] for 4F-PCC vs 0·4 units [1·0] for plasma, p=0·91).
We assessed safety outcomes in the ITT-S population. 49 patients in the 4F-PCC group and 53 patients in the plasma group had at least one adverse event (p=0·54; table 3). The frequency of adverse events and serious adverse events, including those related to treatment, was generally similar between groups. In particular, the proportion of patients with adverse events related to study treatment was eight (9%) in the 4F-PCC group and 15 (17%) in the plasma group (diff erence 8·0%, 95% CI −18·9 to 3·0, p=0·18; post-hoc analysis). Adverse events that occurred in at least 5% of patients in any treatment group after study product infusion are reported in the appendix.
Thromboembolic adverse events were reported during the study for six (7%) patients in the 4F-PCC group and seven (8%) in the plasma group (diff erence −1·1%, 95% CI −10·3 to 8·0, p=0·77). Three (3%) patients in the 4F-PCC group developed fl uid overload or similar cardiac events compared with 11 (13%) in the plasma group (diff erence −9·1%, 95% CI −18·6 to −0·1, p=0·0478). A total of seven patients (three [3%] for 4F-PCC and four [5%] for plasma) experienced possible late bleeding events that were reviewed by the safety adjudication board (appendix).
By the day 45 visit, there were three deaths in the 4F-PCC group and eight in the plasma group, of which one (acute myocardial infarction; plasma group) was considered by the safety adjudication board to be treatment related. The diff erence in rates was −5·7% (95% CI −14·6 to 2·7, p=0·21), and was not considered signifi cant. Individual mortality data are detailed in the appendix. 
Discussion
Because non-inferiority was achieved for both the primary and the coprimary endpoints, non-inferiority was achieved for 4F-PCC compared with plasma overall in this open-label phase 3b study. To our knowledge, this trial is the fi rst adequately powered comparison of 4F-PCC and plasma for rapid VKA reversal in patients needing urgent surgical or invasive interventions. Not only was 4F-PCC non-inferior to plasma for haemostatic effi cacy (the comparison we were primarily powered to test), but it was additionally superior for this endpoint (an eff ect we had less than 70% power to detect). 4F-PCC was also both non-inferior and superior to plasma for the coprimary endpoint of rapid INR reduction.
Only one other randomised trial has addressed this question, a cardiac surgery study with only 20 patients per group that assessed INR reduction but not haemostatic effi cacy. 9 Our results are consistent with fi ndings from this trial and those from previous retrospective cohort studies (including for trauma and spontaneous haemorrhage), which have shown that 4F-PCCs used for VKA reversal can more rapidly replace vitamin K-dependent coagulation factors and lower INR than plasma. [17] [18] [19] [20] The time between start of infusion and start of surgery was signifi cantly shorter in the 4F-PCC group than in the plasma group. The shorter administration time and rapid INR reduction due to higher levels of vitamin K-dependent coagulation factors in 4F-PCC probably contributed to the decreased time to start of surgery that we noted in the 4F-PCC group compared with the plasma group. We do not believe plasma may have been systematically infused more quickly; because it requires ABO typing and thawing, there is local variation in how quickly it can be obtained, and both patient-level and provider-level variation in how quickly the clinical team can infuse it. Because of ethical and logistic considerations, we could not mandate an infusion rate faster than local practice and clinicians could provide. Findings from observational studies have in fact shown substantially slower plasma infusion for VKA reversal in standard clinical practice than we noted in this trial, suggesting that patients in this trial truly did receive plasma as rapidly as was logistically feasible. [21] [22] [23] [24] Whether variations in plasma infusion rates aff ect haemostatic effi cacy is not clear.
Additionally, vitamin K dose and administration route were not rigidly defi ned by the protocol. During trial planning, there were ethical concerns that local teams would need leeway in such dosing, depending on the clinical situation. This factor seems unlikely to be a substantial confounder because we noted no evidence that vitamin K dosing was diff erent between study groups.
Although thromboembolic complications are often listed as a concern in VKA reversal, there was no evidence of an increased risk of such for 4F-PCC compared with plasma. However, the study was not powered to detect between-group diff erences in the incidence of these events. Thus far, no randomised trial has shown a diff erence in thromboembolic event rates between prothrombin complex concentrate and plasma, probably because they were not adequately powered to do so. 9, 11 A recent observational study examining the eff ect of introducing a 4F-PCC to the emergency department found similar results. 17 Two recent comprehensive reviews, based on single-group studies of prothrombin complex concentrates, also concluded that there is a low risk of thromboembolic events in patients treated with prothrombin complex concentrates for VKA reversal, and that underlying disease and dosing may be important factors in increasing risk. 25, 26 Thromboembolism might occur with the same frequency in this patient population irrespective of the means used to reverse VKA. 27, 28 Fluid overload events, however, occurred more frequently in the plasma group than in the 4F-PCC group. Therefore, our data suggest that patients at higher risk of volume overload who need VKA reversal might specifi cally benefi t from 4F-PCC rather than plasma.
We note that most patients in the ITT-E population completed the study to the primary endpoint (86 [99%] of 87 patients in the 4F-PCC group and 79 [98%] of 81 in the plasma group), and safety data to day 10 (including mortality) were available for 164 (93%) of 176 patients. Ten patients withdrew consent and eight withdrew from the study for other reasons; no safety data are available after withdrawal. 40 patients did not complete the study to the 90-day viral safety endpoint, which aff ected only the viral assessment and not our ability to analyse the primary, secondary, or other safety outcomes. Trial discontinuations did not seem to occur disproportionately in one study group compared with the other.
Eight patients had their procedure cancelled or delayed beyond 24 h, suggesting that some enrolled patients did not ultimately need an emergent or urgent procedure. This fi nding highlights the clinical reality of emergency care, in which decisions need to be made rapidly based on information available at the time. The clinical situation can then evolve, and for some patients their clinical status changed in a way that could not be predicted. To maximise generalisability, the criteria for entry included a judgment on the part of the participant's clinical care team that an urgent or emergency procedure was indicated and that pre-procedural urgent VKA reversal was necessary.
Overall study enrolment was fairly slow. We noted that there were several exclusion criteria, and with enrolment occurring in the acute setting, many eligible patients were probably treated by the clinical care teams before the research teams had time to approach participants and go through the informed consent process. Additionally, the scientifi c literature regarding which patients might benefi t from VKA reversal continues to evolve, 1 and many potential participants could have been judged by the clinical teams to not need urgent reversal.
This study had several limitations. First, the study team members, clinicians, and participants could not be blinded to treatment allocation. Such blinding could not logistically or ethically be done because of the underlying diff erences in delivery (PCC is reconstituted and infused quickly in a small volume, whereas type-specifi c plasma must be prepared and dispensed from the local blood bank in multiple bags that must be thawed and infused separately). We attempted to control for this factor by assessing whether the prediction of expected blood loss was diff erent between treatment groups, and found no eff ect. Second, there was variability in timing of plasma infusion. We did note that infusion times were more rapid and consistent than those documented in routine clinical practice, [21] [22] [23] emphasising that plasma infusion was probably done as effi ciently as could be achieved in view of the logistics of delivering it. Third, this study was powered to detect diff erences in effi cacy but not diff erences between groups for safety outcomes; therefore, we cannot rule out diff erences in rare adverse events between treatment groups. Fourth, the haemostatic effi cacy endpoint, although often used in haemostasis trials, includes a potentially subjective component, because clinicians must estimate predicted blood loss and might need to estimate ABL. We optimised this endpoint as much as possible; to our knowledge, it is the best currently available endpoint that can be applied across a range of surgical and invasive interventions.
This study focused on urgent reversal of VKAs rather than direct factor inhibitors. We note that direct factor IIa and Xa inhibitors are now available and are becoming more frequently used as an alternative to VKAs. Because we did not enrol patients taking these newer drugs, we cannot provide much-needed data on how best to reverse them.
In conclusion, these data show that 4F-PCC is an eff ective and superior alternative to plasma in terms of haemostatic effi cacy and rapid INR reduction for the rapid reversal of VKA therapy before urgent procedures (panel).
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